| 8/12/2024 | CV | Market Commentary: JetBlue Airways, Marathon Digital convertible offerings eyed; Revance skyrockets
|
| 7/2/2024 | CV | Market Commentary: Repay to price overnight; Pacira convertible notes plunge outright, contract on hedge
|
| 7/2/2024 | CV | Market Commentary: Morning Commentary: Pacira BioSciences convertibles plunge outright in early trading
|
| 5/10/2024 | CV | Market Commentary: Pacira BioSciences expands on debut; Snap active; Novavax surges on vaccine deal
|
| 5/10/2024 | CV | Market Commentary: Morning Commentary: Pacira BioSciences convertibles hit aftermarket, expand on debut
|
| 5/10/2024 | CV | New Issue: Pacira BioSciences sells $250 million five-year convertibles at 2.125%, up 32.5%
|
| 5/9/2024 | CV | Market Commentary: Pacira BioSciences convertibles eyed; Snap notes in demand; Exact Sciences lower
|
| 5/9/2024 | CV | Market Commentary: Morning Commentary: Pacira BioSciences convertibles eyed; Snap notes in demand
|
| 5/8/2024 | CV | Market Commentary: Pacira on deck; Snap returns to market; Meritage Homes, Southern Co. active; Shopify up
|
| 5/8/2024 | CV | Pacira BioSciences talks $250 million five-year convertibles at 2.125%-2.625%, up 27.5%-32.5%
|
| 10/11/2021 | CV | Market Commentary: Flexion convertibles pop on acquisition; SoFi notes gain outright, lag dollar-neutral
|
| 10/11/2021 | CV | Market Commentary: Morning Commentary: Flexion Therapeutics convertible notes in focus, pop on acquisition
|
| 10/4/2021 | CV | Market Commentary: SoFi Technologies convertibles hit 105 then come in; Pacira aches; Southwest lifts
|
| 7/10/2020 | CV | Pacira greenshoe ups 0.75% five-year convertibles to $402.5 million
|
| 7/9/2020 | CV | Market Commentary: Maxeon Solar convertibles offering ‘unprecedented’; Pacira BioSciences, tech sector gain
|
| 7/8/2020 | CV | Market Commentary: Pacira BioSciences convertibles expand; American Airlines contracts; Microchip active
|
| 7/8/2020 | CV | Market Commentary: Morning Commentary: Pacira BioSciences convertibles in focus early, expand on debut
|
| 7/7/2020 | CV | New Issue: Pacira BioSciences sells $350 million 0.75% convertibles due 2025, up 32.5%
|
| 7/7/2020 | CV | Market Commentary: Pacira BioSciences upsizes convertible notes offering; Livongo expands; Square active
|
| 7/7/2020 | CV | Pacira BioSciences ups convertible notes offering to $350 million, sets final terms
|
| 7/7/2020 | CV | Market Commentary: Morning Commentary: Pacira BioSciences convertible offering eyed; Livongo in focus
|
| 7/6/2020 | CV | Market Commentary: Pacira BioSciences on tap; technology names in focus; China-based convertibles gain
|
| 7/6/2020 | CV | Pacira BioSciences talks $300 million five-year convertible notes at 0.75%-1.25%, up 30%-35%
|
| 5/1/2019 | CV | Market Commentary: Market awaits PROS Holdings convertible notes; Pacira Biosciences expands; DISH improves
|
| 5/1/2019 | CV | Market Commentary: Morning Commentary: PROS Holdings convertible notes in focus; Pacira Biosciences active
|
